{"transactions":[{"id":4632733,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:34:17.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":777332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning October 1, 2027."}],"balance_after":777332,"derivative":{"exercise_price":0.201,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":777332},"source":{"system":"sec-edgar","filing":"0001493152-26-045546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315226045546/ownership.xml","form_type":"4"}},{"id":4627766,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-28T21:01:27.000Z","date":"2026-09-25","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.1975,"value":9875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2026, the Reporting Person filed a Form 4 which inadvertently used Transaction Code \"A\" to report certain open market purchases of shares of Common Stock. As reported in this amendment, the correct Transaction Code is \"P.\""}],"balance_after":905130,"source":{"system":"sec-edgar","filing":"0001493152-26-044629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1963088/000149315226044629/ownership.xml","form_type":"4/A","original_submission_date":"2026-09-28"}},{"id":4627765,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-28T21:01:27.000Z","date":"2026-09-24","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.2173,"value":10865.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2026, the Reporting Person filed a Form 4 which inadvertently used Transaction Code \"A\" to report certain open market purchases of shares of Common Stock. As reported in this amendment, the correct Transaction Code is \"P.\""}],"balance_after":855130,"source":{"system":"sec-edgar","filing":"0001493152-26-044629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1963088/000149315226044629/ownership.xml","form_type":"4/A","original_submission_date":"2026-09-28"}},{"id":4627313,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-28T13:26:49.000Z","date":"2026-09-25","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0.1975,"value":9875.0,"ownership":{"direct":true},"balance_after":905130,"source":{"system":"sec-edgar","filing":"0001493152-26-044471","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1963088/000149315226044471/ownership.xml","form_type":"4"}},{"id":4627312,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-28T13:26:49.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0.2173,"value":10865.0,"ownership":{"direct":true},"balance_after":855130,"source":{"system":"sec-edgar","filing":"0001493152-26-044471","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1963088/000149315226044471/ownership.xml","form_type":"4"}},{"id":708522,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-17T00:21:33.000Z","date":"2026-07-14","kind":"grant","planned":false,"acquired":true,"shares":731030,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":731030,"derivative":{"exercise_price":0.18,"exercise_date":"2026-07-14","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":731030},"source":{"system":"sec-edgar","filing":"0001493152-26-033630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315226033630/ownership.xml","form_type":"4"}},{"id":708521,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-17T00:21:33.000Z","date":"2026-07-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45000,"derivative":{"exercise_price":0.18,"exercise_date":"2026-07-14","expiration_date":"2030-01-26","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001493152-26-033630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315226033630/ownership.xml","form_type":"4"}},{"id":963728,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":154664,"price":0.4041,"value":62499.7224,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":154664,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":154664},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963727,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":154664,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":154664,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":154664},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963726,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":247462,"price":0.4041,"value":99999.3942,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":247462,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":247462},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963725,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":247462,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":247462,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":247462},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":1164432,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1164431,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1164430,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":496499,"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1194120,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:12.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025043935/ownership.xml","form_type":"4"}},{"id":1194119,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:12.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025043935/ownership.xml","form_type":"4"}},{"id":1362706,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F7","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":0.8,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362705,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Notes","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"exercise","planned":false,"acquired":false,"reported_value":275500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":763316},"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362704,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47364,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362703,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68891,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362702,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67735,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362701,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":763316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1362700,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T23:55:45.000Z","date":"2024-11-14","kind":"exercise","planned":false,"acquired":true,"shares":763316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."}],"balance_after":763316,"source":{"system":"sec-edgar","filing":"0000950170-24-128153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017024128153/ownership.xml","form_type":"4"}},{"id":1541612,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-16T21:26:24.000Z","date":"2024-03-20","kind":"other","planned":false,"acquired":true,"shares":354088,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents private placement warrants of the Issuer transferred from Quantum Ventures to the Reporting Person for no consideration. These warrants became exercisable upon consummation of the Business Combination and will expire five years after the Closing, as described in the Issuer's registration statement on Form S-4 (File No. 333-271665), as amended."}],"balance_after":354088,"derivative":{"exercise_price":11.5,"underlying":"Common Stock","underlying_shares":354088},"source":{"system":"sec-edgar","filing":"0001104659-24-047909","document":"tm2411883-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000110465924047909/tm2411883-15_4seq1.xml","form_type":"4"}},{"id":1541611,"issuer":{"id":7491,"kind":"organization","name":"AtlasClear Holdings, Inc.","symbol":"ATCH"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-16T21:26:24.000Z","date":"2024-02-09","kind":"other","planned":false,"acquired":true,"shares":201860,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 9, 2024, the Issuer (f/k/a Calculator New Pubco, Inc.) consummated its initial business combination (the \"Business Combination\") pursuant to the business combination agreement dated November 16, 2022, as amended, among Quantum FinTech Acquisition Corporation (\"Quantum\"), AtlasClear, Inc., a Wyoming corporation, and the other parties thereto. Represents shares of the Issuer's common stock transferred by Quantum Ventures LLC (\"Quantum Ventures\"), to the Reporting Person for no consideration in connection with the closing of the Business Combination (the \"Closing\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 9, 2024, the Issuer (f/k/a Calculator New Pubco, Inc.) consummated its initial business combination (the \"Business Combination\") pursuant to the business combination agreement dated November 16, 2022, as amended, among Quantum FinTech Acquisition Corporation (\"Quantum\"), AtlasClear, Inc., a Wyoming corporation, and the other parties thereto. Represents shares of the Issuer's common stock transferred by Quantum Ventures LLC (\"Quantum Ventures\"), to the Reporting Person for no consideration in connection with the closing of the Business Combination (the \"Closing\")."}],"balance_after":243194,"source":{"system":"sec-edgar","filing":"0001104659-24-047909","document":"tm2411883-15_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000110465924047909/tm2411883-15_4seq1.xml","form_type":"4"}},{"id":1639720,"issuer":{"id":94086,"kind":"organization","name":"Quantum FinTech Acquisition Corp","symbol":"QFTA"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:13:35.000Z","date":"2024-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Business Combination Agreement, dated November 16, 2022, as amended, by and among (i) the Issuer, (ii) Calculator New Pubco, Inc., a Delaware corporation and a wholly-owned Subsidiary of Issuer (\"New Pubco\"), (iii) Calculator Merger Sub 1, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco (\"Merger Sub 1\"), (iv) Calculator Merger Sub 2, Inc., a Delaware corporation and a wholly-owned Subsidiary of New Pubco, (v) AtlasClear, Inc., a Wyoming corporation, (vi) Atlas FinTech Holdings Corp, a Delaware corporation and (vii) Robert McBey, on February 9, 2024, the Issuer merged with and into Merger Sub 1, with Issuer surviving as a wholly-owned subsidiary of New Pubco (the \"Business Combination\"). As a result of the Business Combination, each issued and outstanding share of common stock of the Issuer was exchanged for one share of common stock of New PubCo."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001474506-24-000043","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000147450624000043/primary_doc.xml","form_type":"4"}},{"id":1957637,"issuer":{"id":114547,"kind":"organization","name":"Monterey Innovation Acquisition Corp","symbol":"MTRY"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-14T00:44:11.000Z","date":"2023-03-09","kind":"other","acquired":true,"shares":75000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The shares of common stock (the \"founder shares\") of Monterey Innovation Acquisition Corp. (the \"Company\") are held directly by NorthStar Bio Ventures, LLC (the \"NorthStar Co-Sponsor\"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock (the \"founder shares\") of Monterey Innovation Acquisition Corp. (the \"Company\") are held directly by NorthStar Bio Ventures, LLC (the \"NorthStar Co-Sponsor\"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1417500,"source":{"system":"sec-edgar","filing":"0001104659-23-031926","document":"tm239467-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000110465923031926/tm239467-7_4seq1.xml","form_type":"4"}},{"id":1957636,"issuer":{"id":114547,"kind":"organization","name":"Monterey Innovation Acquisition Corp","symbol":"MTRY"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-14T00:44:11.000Z","date":"2023-03-09","kind":"sale","acquired":false,"shares":570000,"price":0.006,"value":3420.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The shares of common stock (the \"founder shares\") of Monterey Innovation Acquisition Corp. (the \"Company\") are held directly by NorthStar Bio Ventures, LLC (the \"NorthStar Co-Sponsor\"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock (the \"founder shares\") of Monterey Innovation Acquisition Corp. (the \"Company\") are held directly by NorthStar Bio Ventures, LLC (the \"NorthStar Co-Sponsor\"). The Reporting Person is a manager of NorthStar Co-Sponsor. Accordingly, the Reporting Person has voting and dispositive power over the founder shares held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1342500,"source":{"system":"sec-edgar","filing":"0001104659-23-031926","document":"tm239467-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000110465923031926/tm239467-7_4seq1.xml","form_type":"4"}},{"id":2873087,"issuer":{"id":94086,"kind":"organization","name":"Quantum FinTech Acquisition Corp","symbol":"QFTA"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-10T01:55:24.000Z","date":"2021-02-05","kind":"purchase","acquired":true,"shares":501,"price":10.335,"value":5177.835,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased 501 units at a price of $10.335 per unit, for an aggregate purchase price of $5,177.84. Each unit consists of one share of common stock and one warrant to purchase one-half of one share of common stock. The warrants included in the units will become exercisable, if at all, on the later of one year after the closing of the Issuer's initial public offering or the consummation of the Issuer's initial business combination."}],"balance_after":41334,"source":{"system":"sec-edgar","filing":"0001213900-21-007855","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000121390021007855/ownership.xml","form_type":"4"}}]}